Table 1.
Patient characteristics.
| Variable | Patients with recurrence, no. of patients (%) |
|---|---|
| Age, median (range) | 55 years (27 to 79 years) |
| Race | |
| Caucasian | 63 (80.8%) |
| African American | 10 (12.8%) |
| Hispanic | 5 (6.4%) |
| ECOG performance status | |
| 0 | 17 (21.8%) |
| 1 | 30 (38.5%) |
| Unknown | 31 (39.7%) |
| Presenting symptoms | |
| Abnormal uterine bleeding | 35 (44.9%) |
| Pelvic pain | 13 (16.7%) |
| Incidental finding | 4 (5.1%) |
| Other | 6 (7.7%) |
| Unknown | 20 (25.6%) |
| Size, median (range) | 7.1 cm (0.4 to 25 cm) |
| ≤5 cm | 14 (17.9%) |
| >5 cm | 36 (46.2%) |
| Unknown | 28 (35.9%) |
| Myometrial invasion | |
| No myometrial invasion | 12 (15.4%) |
| ≤½ of myometrium | 26 (33.3%) |
| >½ of myometrium | 8 (10.3%) |
| Unknown | 32 (41.0%) |
| Sarcomatous overgrowth | |
| Absent | 15 (19.2%) |
| Present | 58 (74.4%) |
| Unknown | 5 (6.4%) |
| Lymph node involvement | |
| None | 34 (43.6%) |
| Present | 1 (1.3%) |
| No lymph node sampling | 39 (50.0%) |
| Unknown | 4 (5.1%) |
| Uterine adenosarcoma FIGO stage at diagnosis | |
| Ia | 7 (9.0%) |
| Ib | 19 (24.4%) |
| Ic | 4 (5.1%) |
| I (nos.) | 9 (11.6%) |
| IIa | 7 (9.0%) |
| IIb | 12 (15.4%) |
| IIIa | 7 (9.0%) |
| IIIb | 4 (5.1%) |
| IIIc | 1 (1.3%) |
| IVa | 4 (5.1%) |
| IVb | 1 (1.3%) |
| Unknown | 3 (3.8%) |
| Tumor location | |
| Uterine corpus | 58 (74.4%) |
| Ovary | 5 (6.4%) |
| Cervix | 2 (2.6%) |
| Pelvic primary | 11 (14.1%) |
| Vagina | 1 (1.3%) |
| Unknown | 1 (1.3%) |
| Initial treatment strategy | |
| Surgery alone | 45 (57.7%) |
| Surgery + radiation (adjuvant or neoadjuvant) | 22 (28.2%) |
| Surgery + chemotherapy (adjuvant or neoadjuvant) | 6 (7.7%) |
| Surgery + radiation + chemotherapy | 4 (5.1%) |
| Surgery + hormonal therapy | 1 (1.3%) |
| Bilateral salpingo-oophorectomy | |
| Yes | 55 (70.5%) |
| No | 13 (16.7%) |
| History of prior BSO | 9 (11.5%) |
| Unknown | 1 (1.3%) |
| Lymphadenectomy | |
| Yes | 31 (39.7%) |
| No | 43 (55.1%) |
| Unknown | 4 (5.1%) |
| Vital status | |
| Alive | 24 (30.8%) |
| Dead | 54 (69.2%) |
| Recurrence | |
| Any recurrence | 78 |
| Local (abdomen/pelvis) | 61 (78.2%) |
| Local and distant | 11 (14.1%) |
| Distant | 5 (6.4%) |
| Unknown | 1 (1.3%) |
| Median follow-up | 8.2 years |
This table described patient demographics (age and race), presenting symptoms, performance status, tumor pathologic characteristics (size, myometrial invasion, sarcomatous overgrowth, and lymph node involvement), tumor stage, tumor location, initial treatments (surgery, radiation, chemotherapy, BSO, and lymphadenectomy), vital status (alive versus dead), and recurrence location for patients with recurrence.